• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发和同基因 Kras 驱动的小鼠肿瘤模型的免疫景观差异。

Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models.

机构信息

Cancer Biology Graduate Program, Carver College of Medicine, University of Iowa, 285 Newton Rd, 3269C CBRB, Iowa City, IA, 52246, USA.

Medical Scientist Training Program, University of Iowa, Iowa City, IA, USA.

出版信息

Sci Rep. 2021 Jan 13;11(1):1098. doi: 10.1038/s41598-020-80216-1.

DOI:10.1038/s41598-020-80216-1
PMID:33441747
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7806664/
Abstract

Immune cells play critical functions in cancer, and mice with intact immune systems are vital to understanding tumor immunology. Both genetically engineered mouse models (GEMMs) and syngeneic cell transplant approaches use immunocompetent mice to define immune-dependent events in tumor development and progression. Due to their rapid and reproducible nature, there is expanded interest in developing new syngeneic tools from established primary tumor models. However, few studies have examined the extent that syngeneic tumors reflect the immune profile of their originating primary models. Here, we describe comprehensive immunophenotyping of two well-established GEMMs and four new syngeneic models derived from these parental primary tumors. To our knowledge, this is the first systematic analysis comparing immune landscapes between primary and orthotopic syngeneic tumors. These models all use the same well-defined human-relevant driver mutations, arise at identical orthotopic locations, and are generated in mice of the same background strain. This allows for a direct and focused comparison of tumor immune landscapes in carefully controlled mouse models. We identify key differences between the immune infiltrate of GEMM models and their corresponding syngeneic tumors. Most notable is the divergence of T cell populations, with different proportions of CD8+ T cells and regulatory T cells across several models. We also observe immune variation across syngeneic tumors derived from the same primary model. These findings highlight the importance of immune variance across mouse modeling approaches, which has strong implications for the design of rigorous and reproducible translational studies.

摘要

免疫细胞在癌症中发挥着关键作用,免疫系统健全的小鼠对于理解肿瘤免疫学至关重要。基因工程小鼠模型 (GEMM) 和同基因细胞移植方法都使用免疫功能正常的小鼠来定义肿瘤发生和进展中免疫依赖的事件。由于其快速和可重复的性质,人们对从已建立的原发性肿瘤模型开发新的同基因工具产生了更大的兴趣。然而,很少有研究检查同基因肿瘤在多大程度上反映了其起源原发性模型的免疫特征。在这里,我们描述了两种成熟的 GEMM 和从这些亲本原发性肿瘤衍生的四种新的同基因模型的全面免疫表型。据我们所知,这是首次对原发性和原位同基因肿瘤之间的免疫景观进行系统分析。这些模型都使用相同的明确定义的人类相关驱动突变,在相同的原位位置出现,并在相同的背景品系小鼠中产生。这允许在精心控制的小鼠模型中直接和集中地比较肿瘤免疫景观。我们确定了 GEMM 模型和相应的同基因肿瘤中免疫浸润之间的关键差异。最值得注意的是 T 细胞群体的分歧,几个模型中的 CD8+T 细胞和调节性 T 细胞的比例不同。我们还观察到来自同一原发性模型的同基因肿瘤之间的免疫变化。这些发现强调了在不同的小鼠建模方法中存在免疫差异的重要性,这对严格和可重复的转化研究的设计具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/6aa6d7043cb9/41598_2020_80216_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/4f7a86209946/41598_2020_80216_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/51f11ec7bda8/41598_2020_80216_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/d2320416a8f3/41598_2020_80216_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/f6cc18e03403/41598_2020_80216_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/0758ea477a44/41598_2020_80216_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/99c9aa33530c/41598_2020_80216_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/0286cf05c4dc/41598_2020_80216_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/6aa6d7043cb9/41598_2020_80216_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/4f7a86209946/41598_2020_80216_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/51f11ec7bda8/41598_2020_80216_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/d2320416a8f3/41598_2020_80216_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/f6cc18e03403/41598_2020_80216_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/0758ea477a44/41598_2020_80216_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/99c9aa33530c/41598_2020_80216_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/0286cf05c4dc/41598_2020_80216_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e6d/7806664/6aa6d7043cb9/41598_2020_80216_Fig8_HTML.jpg

相似文献

1
Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models.原发和同基因 Kras 驱动的小鼠肿瘤模型的免疫景观差异。
Sci Rep. 2021 Jan 13;11(1):1098. doi: 10.1038/s41598-020-80216-1.
2
Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.用于过继性 T 细胞转移治疗的临床相关原位胰腺癌模型。
J Immunother Cancer. 2024 Jan 8;12(1):e008086. doi: 10.1136/jitc-2023-008086.
3
The KRAS Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.KRAS 抑制剂 MRTX849 重塑肿瘤免疫微环境并增强肿瘤对检查点抑制剂治疗的敏感性。
Mol Cancer Ther. 2021 Jun;20(6):975-985. doi: 10.1158/1535-7163.MCT-20-0462. Epub 2021 Mar 15.
4
Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.通过可溶性蛋白或表达Ras的大肠杆菌诱导针对Ras癌蛋白的T细胞免疫。
J Natl Cancer Inst. 1995 Dec 20;87(24):1853-61. doi: 10.1093/jnci/87.24.1853.
5
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.下一代原位甲状腺癌模型:BRAF V600E 阳性乳头状和间变性甲状腺癌的免疫活性原位小鼠模型。
Thyroid. 2014 Apr;24(4):705-14. doi: 10.1089/thy.2013.0483. Epub 2014 Jan 24.
6
Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.Rnf43 缺失加速 Kras 介导的肿瘤发生并重塑胰腺导管腺癌的肿瘤免疫微环境。
Gastroenterology. 2022 Apr;162(4):1303-1318.e18. doi: 10.1053/j.gastro.2021.12.273. Epub 2021 Dec 30.
7
Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.具有共发生致癌突变和肿瘤突变负担增加的新型 Kras 突变型非小细胞肺癌鼠模型。
Cancer Immunol Immunother. 2021 Aug;70(8):2389-2400. doi: 10.1007/s00262-020-02837-9. Epub 2021 Jan 28.
8
Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator.胆固醇调节剂阿伐麦布增强 Kras 肽癌症疫苗。
EBioMedicine. 2019 Nov;49:72-81. doi: 10.1016/j.ebiom.2019.10.044. Epub 2019 Oct 31.
9
Primary tumor-induced immunity suppresses bone metastases of breast cancer in syngeneic immunocompetent mouse models.在同基因免疫活性小鼠模型中,原发性肿瘤诱导的免疫抑制乳腺癌的骨转移。
Bone. 2024 Jan;178:116944. doi: 10.1016/j.bone.2023.116944. Epub 2023 Oct 19.
10
Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors.比较常见的具有人类肿瘤特征的同源小鼠模型的分子和细胞表型。
BMC Genomics. 2020 Jan 2;21(1):2. doi: 10.1186/s12864-019-6344-3.

引用本文的文献

1
The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the murine model of sarcoma.人类STING激动剂E7766可诱导免疫原性肿瘤清除,在肉瘤小鼠模型中与肿瘤内在的STING表达无关。
Oncoimmunology. 2025 Dec;14(1):2534912. doi: 10.1080/2162402X.2025.2534912. Epub 2025 Jul 22.
2
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies.横纹肌肉瘤:当前的治疗方法、挑战及未来的治疗策略途径
Cancers (Basel). 2023 Nov 2;15(21):5269. doi: 10.3390/cancers15215269.
3
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.

本文引用的文献

1
Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in -deleted Mouse Models of Sarcoma.肿瘤亚型决定嵌合多肽纳米颗粒化疗在肉瘤 -/- 小鼠模型中的治疗反应。
Clin Cancer Res. 2020 Sep 15;26(18):5036-5047. doi: 10.1158/1078-0432.CCR-19-2597. Epub 2020 Jul 27.
2
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.癌症中MHC I类分子下调:潜在机制及癌症免疫治疗的潜在靶点
Cancers (Basel). 2020 Jul 2;12(7):1760. doi: 10.3390/cancers12071760.
3
Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
CDK4/6-MEK 抑制在 MPNSTs 中引起浆细胞浸润、对 PD-L1 阻断的敏感性增加和肿瘤消退。
Clin Cancer Res. 2023 Sep 1;29(17):3484-3497. doi: 10.1158/1078-0432.CCR-23-0749.
4
Loss of Nf1 and Ink4a/Arf Are Associated with Sex-Dependent Growth Differences in a Mouse Model of Embryonal Rhabdomyosarcoma.在胚胎性横纹肌肉瘤小鼠模型中,Nf1和Ink4a/Arf的缺失与性别依赖性生长差异相关。
Curr Issues Mol Biol. 2023 Feb 2;45(2):1218-1232. doi: 10.3390/cimb45020080.
5
Low-Cost, High-Pressure-Synthesized Oxygen-Entrapping Materials to Improve Treatment of Solid Tumors.低成本、高压合成的氧捕获材料,改善实体瘤治疗效果。
Adv Sci (Weinh). 2023 Apr;10(10):e2205995. doi: 10.1002/advs.202205995. Epub 2023 Feb 2.
6
Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.肿瘤内 STING 激活可导致 KP 软组织肉瘤模型中的持久免疫原性肿瘤消除。
Front Immunol. 2023 Jan 9;13:1087991. doi: 10.3389/fimmu.2022.1087991. eCollection 2022.
7
Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism.通过免疫非依赖机制,用低剂量地西他滨增强化疗。
JCI Insight. 2022 Nov 22;7(22):e159419. doi: 10.1172/jci.insight.159419.
8
Emerging mechanisms of immunotherapy resistance in sarcomas.肉瘤免疫治疗耐药的新机制
Cancer Drug Resist. 2022 Mar 5;5(1):199-213. doi: 10.20517/cdr.2021.111. eCollection 2022.
9
The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.KrasG12D;Trp53fl/fl 小鼠未分化多形性肉瘤模型中巨噬细胞丰富,淋巴细胞稀少,并对免疫检查点阻断具有抗性。
PLoS One. 2021 Jul 9;16(7):e0253864. doi: 10.1371/journal.pone.0253864. eCollection 2021.
程序性细胞死亡1配体-1在骨肉瘤和软组织肉瘤患者中的预后价值:基于3680例患者的系统全面的Meta分析
Front Oncol. 2020 Jun 2;10:749. doi: 10.3389/fonc.2020.00749. eCollection 2020.
4
Immune profiling of pediatric solid tumors.儿科实体瘤的免疫分析。
J Clin Invest. 2020 Jul 1;130(7):3391-3402. doi: 10.1172/JCI137181.
5
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.免疫图谱可预测急性髓系白血病的化疗耐药性和免疫治疗反应。
Sci Transl Med. 2020 Jun 3;12(546). doi: 10.1126/scitranslmed.aaz0463.
6
Distinct Tumor Microenvironments Are a Defining Feature of Strain-Specific CRISPR/Cas9-Induced MPNSTs.不同的肿瘤微环境是特定 CRISPR/Cas9 诱导的 MPNST 菌株特异性的一个定义特征。
Genes (Basel). 2020 May 23;11(5):583. doi: 10.3390/genes11050583.
7
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.肉瘤中肿瘤相关巨噬细胞及巨噬细胞相关免疫检查点表达
Oncoimmunology. 2020 Apr 12;9(1):1747340. doi: 10.1080/2162402X.2020.1747340. eCollection 2020.
8
B cells are associated with survival and immunotherapy response in sarcoma.B 细胞与肉瘤的生存和免疫治疗反应有关。
Nature. 2020 Jan;577(7791):556-560. doi: 10.1038/s41586-019-1906-8. Epub 2020 Jan 15.
9
Current and Future Treatment Strategies for Rhabdomyosarcoma.横纹肌肉瘤的当前及未来治疗策略
Front Oncol. 2019 Dec 20;9:1458. doi: 10.3389/fonc.2019.01458. eCollection 2019.
10
Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.免疫肿瘤学领域中更好地转化为临床的忠实临床前小鼠模型。
Int J Clin Oncol. 2020 May;25(5):831-841. doi: 10.1007/s10147-019-01520-z. Epub 2019 Aug 12.